<DOC>
	<DOCNO>NCT01092390</DOCNO>
	<brief_summary>In application investigator describe plan randomize control cross-over trial determine effect omega-3 fatty acid supplementation urine protein excretion 30 adult diabetes ( NIDDM ) kidney disease define presence proteinuria .</brief_summary>
	<brief_title>Go Fish : Omega-3 Fatty Acid Supplementation Diabetes-Related Kidney Disease</brief_title>
	<detailed_description>Diabetes common cause end-stage kidney disease United States . Half patient diabetes develop kidney disease . The benefit omega-3 fatty acid show animal model kidney injury . Mechanistic study omega-3 fatty acid supplement support biological plausibility : omega-3 supplement show improve vascular reactivity , low oxidative stress , reduce inflammation , beneficial effect metabolism eicosanoids favor synthesis vasodilatory prostaglandins thromboxanes . However , spite overwhelming evidence potential benefit dietary omega-3 fatty acid prevent slow progression kidney disease adult NIDDM , clinical trial provide evidence support recommendation supplementation lacking . The current recommendation omega-3 intake adult , one gram/day DHA+EPA , base evidence cardiovascular disease risk ( CVD ) reduction . Whether omega-3 fatty acid prevents slow progression diabetic kidney disease , whether current recommend dose adequate modify disease , whether high dose recommend , need determine . In set , propose conduct randomize placebo-controlled cross-over clinical trial determine effect daily dose omega-3 fatty acid supplementation ( 4.0 g/day ) compare placebo urine protein excretion biomarkers kidney injury function adult diabetes proteinuria .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>Participants diagnosis diabetes ( either oral medication diet control ) Have average systolic blood pressure ( SBP ) &lt; 150 diastolic blood pressure ( DBP ) &lt; 90 mmHg Have quantify proteinuria urine albumin/creatinine ratio &gt; 17 mg/g ( men ) &gt; 25 mg/g ( woman ) ( i.e . least microalbuminuria ) . Participants must stable dos antihypertensive , hypoglycemic , lipid lower medication minimum two month prior randomization . Participants must agree stay stable dos diabetes , antihypertensive lipid medication duration study . Major exclusion criterion poorly control diabetes ( Hemoglobin A1c &gt; 9 % ) Use insulin Use fish oil supplement unwilling stop fish oil supplement one month prior randomization refrain supplement study Stage 4 stage 5 CKD screen urine protein/creatinine ratio &gt; 2.5 .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>randomize trial</keyword>
	<keyword>omega three fatty acid</keyword>
</DOC>